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Abstract
Background—Evidence-based guidelines recommend routine surveillance, including office
visits and testing, to detect new and recurrent disease among breast and colorectal cancer
survivors. The extent to which surveillance practice is consistent with guideline recommendations
or may vary by age is not known.
Methods—Cohorts of adult patients diagnosed with breast (n=6,205) and colorectal (n=2,297)
cancer between 2000 and 2008 and treated with curative intent in four, geographically diverse,
managed care environments were identified via tumor registries. Kaplan-Meier estimates were
used to describe time to initial and subsequent surveillance service receipt. Cox proportional
hazards models evaluated the relationship between patient characteristics and receipt of metastatic
screening.
Results—Within 18-months of treatment, 87.2% of breast cancer survivors received
recommended mammograms, with significantly higher rates for patients aged 50–65. Among
colorectal cancer survivors, only 55.0% received recommended colon examinations, with
significantly lower rates for those ≥ aged 75. Most breast (64.7%) and colorectal (73.3%) cancer
survivors received non-recommended metastatic disease testing. In breast cancer, factors
associated with metastatic disease testing include white race (HR=1.13), comorbidities (HR=1.17),
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and younger age. In colorectal cancer, these factors included younger age and comorbidities
(HR=1.10).
Conclusions—Among an insured population, we found wide variation in the use of surveillance
care by age and relative to guideline recommendations. Breast cancer survivors have high rates of
both guideline recommended recurrence testing and non-guideline recommended metastatic
testing. Only about half of colorectal cancer survivors receive recommended tests but over two
thirds received metastatic testing.
Keywords
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INTRODUCTION
In 2006, the Institute of Medicine (IOM) recommended that cancer survivors receive
ongoing surveillance care based on a follow-up plan that is clearly and effectively
explained1. Evidence- and consensus-based guidelines from the National Comprehensive
Cancer Network (NCCN)2,3, the American Society of Clinical Oncology (ASCO)4,5, and
other specialty-oriented medical societies6–9 outline recommended schedules for ongoing
surveillance care after cancer treatment with curative intent. Although recommendations
vary to some extent in terms of type and timing of care, NCCN and ASCO guidelines for
breast and colorectal cancer survivors recommend a course that consists of periodic physical
examinations and screening for recurrent and metastatic disease via imaging and other
procedures.
Relatively little is known about the quality of care delivered to cancer survivors. Prior
studies among breast and colorectal cancer survivors have found deviations in surveillance
care patterns relative to evidence-based guidelines as well as variation in surveillance care
use by patient socio-demographic characteristics, including race and income. However, such
studies have been limited to survivors receiving care from one delivery organization10–16 or
those enrolled in Medicare17–21. As such, the care received by survivors who are aged 64
years or younger is not well documented. Furthermore, no studies have been conducted
since the IOM report was issued.
Using cohorts of breast and colorectal cancer survivors receiving care from four
geographically diverse health maintenance organizations between 2000 and 2008, we
evaluated the extent to which surveillance care use was consistent with guideline
recommendations. Of specific interest was evaluation of the variability in surveillance care
use by age at diagnosis.
METHODS
Study Population and Setting
This study was conducted within four large non-profit integrated health systems: Group
Health Cooperative, Health Alliance Plan/Henry Ford Health System, Kaiser Permanente
Colorado, and Kaiser Permanente Northwest. These plans are all members of the Cancer
Research Network (CRN) (NCI Cooperative Agreement No. U19 CA79689, Increasing
Effectiveness of Cancer Control Interventions), an initiative of the National Cancer Institute
designed to conduct research on cancer prevention, early detection, treatment, long-term
care, surveillance, and cancer communication and dissemination and implementation
research.
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Data available from each organization’s tumor registry were used to identify patients aged ≥
18 years who were diagnosed between January 1, 2000 and December 31, 2008 with non-
metastatic breast (ICD O C50.0–C50.9) or colorectal (ICD O C18.0–C18.9, C19.9, C20.9,
and C26.0) cancer. Patients eligible for study inclusion were those continuously enrolled in
the health plan for the 1-year period preceding their date of cancer diagnosis. Patients for
whom no stage of disease information was available at the time of diagnosis were excluded.
Patients were also excluded if they had a previous diagnosis of invasive cancer, had distant
metastases at time of diagnosis, or did not receive treatment with curative intent (i.e.,
surgery). The breast cancer cohort was limited to females and excluded women who had a
bilateral mastectomy or two separate occurrences of a unilateral mastectomy on different
dates.
Sample patients were followed from an “index date,” defined as three months following the
last curative surgical procedure, to the first of the following end points (“end date”): death;
tumor recurrence; diagnosis of a second primary cancer; health plan disenrollment, five
years after initial cancer diagnosis; or the end of the follow-up period (December 31, 2008).
Previous findings indicate that altering assignment of the index date to exclude from
consideration care received within the first six and nine months after surgical treatment (vs.
three months), does not alter results or conclusions13. Institutional Review Boards at each of
the four participating organizations approved all aspects of the study protocol.
Data Sources and Measures
Automated electronic medical record (EMR) and claims data linked to tumor registry data
were accessed to obtain patient demographic characteristics, date of cancer diagnosis, stage
at diagnosis, and comorbidities in the 12-month period preceding diagnosis for each patient.
Patient demographics included age at diagnosis, gender, and race (black, white, and other).
Using patients’ residential street address combined with 2000 US Census tract data we
estimated the median household income for each patient’s residential neighborhood. Clinical
measures included stage of disease at diagnosis, date of any cancer recurrence(s) (defined as
either local recurrence or the occurrence of a second primary tumor) within five years of the
index date, and date of death. We measured recurrence(s) using the algorithm for measuring
disease-free survival described in Lamont et al. (2006).22 We summarized disease stages
into three groups: in situ (AJCC general stage 0), localized (AJCC general stage 1), and
regional (AJCC general stages 2–5; i.e., regional by direct extension, lymph nodes, both, or
not otherwise specified).
In addition to data available via the tumor registries, EMR and claims data were reviewed
between the patient’s “index date” and “end date.” For each organization, these data sources
contain comprehensive visit and procedure information for any outpatient encounter to a
physician, laboratory, and imaging department. These data were used to compute receipt of
testing services, and treatment with surgery, chemotherapy, hormone therapy, radiation, and
combination therapies. The Deyo adaptation of the Charlson comorbidity index and each of
its component diagnostic subgroups were constructed using inpatient and outpatient
diagnostic information available in the 12-month period preceding diagnosis.23
Surveillance Care Receipt
The primary outcome of interest is the time to receipt of recommended surveillance care.
For both breast and colorectal cancer, we observed three distinct types of surveillance:
physical examinations; testing for local recurrence; and testing for metastatic disease.
Physical examinations performed by a primary care provider, medical oncologist, radiation
oncologist, general surgeon or gastroenterologist (for colorectal cancer only) were included.
For breast cancer, local recurrence tests included mammography, magnetic resonance
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imaging (MRI), and ultrasound, whereas for colorectal cancer, local recurrence testing
included colonoscopy, sigmoidoscopy, and barium enema. Procedures to detect metastatic
disease recurrence included chest radiograph, computerized tomography of the chest,
abdomen, pelvis or head, MRI of the chest, abdomen, pelvis or head, bone scan, gallium
scan, liver/spleen scan, and abdominal or pelvic ultrasound. Because surveillance care
guidelines recommend not only type of care, but also its timing, we evaluated the frequency
of care receipt and the time interval between initial and subsequent receipt of the same type
of examination/test.
Finally, we evaluated whether the patient received NCCN and ASCO guideline-
recommended surveillance care. This was done by estimating the time (in days) from index
date to the date by which a patient had received the minimum amount and type of
surveillance testing recommended by the guideline. For patients with breast cancer, this
included two physical examinations and one mammogram, while for colorectal cancer this
included two physical examinations and one complete examination of the colon. In addition
to time, we also report the proportion of patients who received recommended care within 18
months following treatment with curative intent. This was done because care receipt in
practice rarely falls neatly within 12-month periods.
Analytical Approach
Because of the differing lengths of follow up among sample members, we used Kaplan-
Meier estimates to evaluate the median time to initial and subsequent care receipt by type of
examination/test. We report the proportion of patients receiving care within the
corresponding 18 months using actuarial results. Kaplan-Meier estimates were also used to
determine cumulative incidences of the receipt of the minimum recommended surveillance
care. Estimates were evaluated for the entire population of survivors as well as separately for
four age groups: <50, 50–64, 65–74, and ≥75. We plotted values as the probability of the
complement so that graphs reflected time to receipt of care. We used Cox proportional
hazards models which also account for differing length of follow up among sample members
to quantify the effects of baseline clinical and sociodemographic patient characteristics,
including patient age group, on the risk of receiving metastatic testing (a non-recommended
care type) within the initial 18 months. In addition to age, models adjusted for the patient’s
race, sex (only for the colorectal cancer sample), stage, neighborhood household income,
Charlson-Deyo comorbidity index, and health plan. All analyses were performed using SAS




The characteristics of the 6,205 breast cancer patients and 2,297 colorectal cancer patients
by health plan are shown in Table 1. The mean ages of the cohorts were 62.4 (±12.6) for
breast cancer patients and 68.6 (±12.2) for colorectal cancer patients with 57% of the breast
cancer patients under the age of 65 and 35% of the colorectal cancer patients under the age
of 65. While the study included only female breast cancer patients, the gender distribution
for colorectal cancer was 49% male and 51% female. African Americans represented 8% of
the breast cancer sample and 8% of the colorectal cancer sample. For breast cancer, most
tumors were classified as local stage (80%), while among the colorectal cancer group there
was a more even distribution between local (49%) and regional disease (51%). Per study
eligibility criteria, all patients received curative surgical treatment. The overall median
length of observation was 49.5 months for breast cancer and 40.9 months for colorectal
cancer patients. Evidence of recurrent cancer or a second primary tumor occurred in 13% of
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breast cancer patients and 22% of colorectal cancer patients. Almost 96% of breast cancer
patients survived through the end of follow-up, compared with 90% for colorectal cancer
patients. This survival rate was 99% for breast cancer patients aged <65 years versus 91%
for those aged ≥65 years. In colorectal cancer, the survival rate for patients aged <65 years
was 97% compared with 86% for patients aged ≥65 years. Survival differences by age group
(under/over 65) in both the breast and colorectal cancer cohorts were statistically significant
(data not shown).
Surveillance Care Receipt
Results from the Kaplan-Meier survival analysis for time to initial and subsequent receipt of
specific examinations and procedures are shown in Table 2. These results are presented for
all ages combined, and separately for each of the four aforementioned age groups. For both
cancer sites, the overwhelming majority of patients (97.1% of breast cancer and 98.2% of
colorectal cancer patients) received the minimum recommended number of physical
examinations within the initial 18 months after treatment with curative intent. The median
time to receipt of the recommended physical examinations ranged from 1.6 months among
breast cancer patients to 1.8 months among colorectal cancer patients. If we consider the
time to subsequent receipt of physical examinations, then a majority of cancer survivors
received at least twice the number of recommended physical examinations within the initial
year following treatment. Among both breast and colorectal cancer patients, the median time
to receipt of a subsequent physical examination was just over two months, implying that
many patients received two physical examinations within the initial four months following
treatment.
Most breast cancer patients received recommended local recurrence testing within 18
months. Among this group, 87.2% received mammograms within 18 months of treatment,
with a median time of 7.2 months. Only 55% of colorectal cancer survivors received a
complete examination of the colon within the first 18 months. The median time to initial
receipt of this test was 13.3 months. Table 2 also shows the relatively common use of
metastatic disease testing among cancer survivors. Almost 65% of breast cancer survivors
and 73% of colorectal cancer survivors received some type of metastatic disease testing
within 18 months after treatment with curative intent. The median time to initial receipt of
metastatic testing in breast cancer was 9.4 months, and 6.1 months in colorectal cancer.
When comparing the four age groups among breast cancer survivors, the proportion of
patients receiving a mammogram within 18 months of curative intent treatment was similar
among the middle two age groups, with 89% and 91% respectively, but significantly lower
with the aged <50 group (82%) and the aged ≥75 group (82%). Among colorectal cancer
survivors, the younger three age groups had similar rates of colon examinations within 18
months of curative intent treatment, with 63%, 64%, and 62% respectively, but a
significantly lower rate among the aged ≥75 (41%). Meanwhile we observe a small, but
significant increase in the receipt of metastatic testing within the first 18 months following
curative intent associated with increasing age, for both breast and colorectal cancer
survivors.
Figure 1 shows estimates of the time to minimum guideline recommended surveillance care
during the initial year (i.e. two physical examinations and one mammogram for breast
cancer survivors; and two physical examinations and one complete examination of the colon
for colorectal cancer survivors), stratified by age group. Overall, almost 90% of breast
cancer survivors receive the recommended surveillance care within 18 months of treatment
with curative intent, although the rates are higher for the patients aged 50 through 74 years
compared to their younger and older counterparts. Of note, is the fact that, regardless of age,
the overwhelming majority of these patients received that care well before 12 months
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following their treatment with curative intent. On the other hand, just over half of colorectal
cancer survivors received recommended surveillance care within 18 months of treatment
with curative intent, with all age groups having similar rates except for the aged ≥75 years
who recorded significantly lower rates of receipt.
Factors Associated with Metastatic Disease Testing
Results of the Cox proportional hazards models for receipt of metastatic disease testing
within 18 months of curative intent treatment, among breast cancer patients, are presented in
Table 3. As shown in the table, a diagnosis in any of the three younger age groups,
compared to those aged ≥75, was associated with a higher likelihood of receiving metastatic
testing for aged <50 (HR, 1.13), for aged 50–64 (HR, 1.15), and for aged 65–74 (HR, 1.13).
The diagnosis of in situ (HR, 0.31) or regional (HR, 0.57) disease decreased the likelihood
of receiving metastatic disease surveillance testing. White breast cancer survivors (HR,
1.13), those with a higher Charlson-Deyo comorbidity index (HR, 1.17), and those receiving
care at Health Plan 1 (HR, 1.76) had a greater likelihood of receiving metastatic testing. We
also found significant (p<0.01) variation in the use of metastatic testing by health plan.
Table 4 shows the results of the Cox proportional hazards models for receipt of metastatic
disease testing within 18 months of curative intent treatment, among colorectal cancer
patients. Testing for metastatic disease was more likely to occur among patients aged <50
years (HR, 1.31), or aged 50–64 years (HR, 1.25), or aged 65–74 years (HR, 1.11). Patients
with more comorbidities (HR, 1.10) were also more likely to receive metastatic testing, but
less likely if they were diagnosed with in situ (HR, 0.30) or local (HR, 0.60) disease. Testing
for metastatic disease also varied significantly by health plan (p<0.01).
DISCUSSION
Among geographically diverse cohorts of breast and colorectal cancer survivors, we found
deviations in the surveillance care received relative to guideline recommendations for
physical examinations, and local recurrence and metastatic disease screening. Although
many cancer survivors appear to be receiving the minimum recommended surveillance care,
a large number of cancers survivors, regardless of age, are still not receiving minimum care
recommendations while others are receiving non-recommended metastatic disease testing, as
well as recommended care at a greater frequency than what is recommended.
In the integrated delivery systems studied here, the overwhelming majority of breast and
colorectal cancer survivors received the minimum recommended number of post-treatment
physical exams. In fact, the majority of both breast and colorectal cancer survivors,
regardless of age or location of care, appear to receive physical exams more frequently than
is recommended by national guidelines. However, despite such exams and national guideline
recommendations, almost half of the colorectal cancer cohort failed to receive a complete
examination of the colon within 18 months of treatment. On the other hand the majority of
breast cancer survivors received recommended recurrence testing. Regardless of cancer site,
more than two thirds of survivors particularly those who are younger received some type of
metastatic disease testing within 18 months—none of which is recommended by evidence-
based guidelines. Furthermore, there were significant differences in the receipt of metastatic
testing among health plans that may be a result of regional and practice variations. In
addition to these organizational differences, our findings highlight the patient factors
associated with metastatic disease testing use. In fact, very little is known about what
clinical factors such as type and duration of treatment that clinicians might consider when
making surveillance care recommendations to their patients. Clearly there is more to be
understood about not only the multi-level factors associated with the receipt of under- and
over-care relative to guideline recommendations, but also the health and economic
implications of such care use.
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Compared to prior studies,10,12,14,16,18 our results seem to illustrate an increase in the receipt
of recommended mammograms within 18 months of curative intent treatment as well as a
declinein the use of non-recommended metastatic testing among both breast and colorectal
cancer survivors. However, these improvements in care quality seemed to occur
concurrently with a decrease in receipt of recommended colon examinations among
colorectal cancer patients. Furthermore, consistent with prior studies,10,15,21,24 we found
that age, stage, race (in breast cancer only), and comorbidities at diagnosis impacted the
receipt of metastatic disease testing. Additional clinical evidence is needed to justify
whether such variations reflect an opportunity for quality improvement from a public health
perspective.
The IOM recommends that all cancer survivors receive a survivorship care plan that
includes clear and effective recommendations regarding preventive practices and specific
information about the timing and content of recommended follow-up1. European studies
have highlighted that patients exhibit a positive attitude towards follow-up care and want
follow-up plans to be tailored to their specific needs26–29. There is growing evidence that
survivors in the US have similar preferences, and that they wish to collaborate with
providers in making medical decisions and want to receive care plan information
directly30–32. It remains unknown whether the patterns of follow-up care observed here are
consistent with those preferences. However, as we have no evidence that such plans were
routinely used during the time of observation in any of the organizations studied here, it is
likely safe to assume that the observed patterns of follow-up are as much a result of a lack of
explicit follow-up planning and care coordination as a coordinated and well-planned effort.
Given that each of the participating organizations is an integrated delivery system with a
comprehensive electronic medical record system, and each routinely scores well on publicly
available quality metrics33, it seems clear that while substantive quality gains may have been
made at either end of the cancer care continuum, as the IOM report points out, care
delivered during the transition from cancer patient to cancer survivor more often than not is
inadequate.
These conclusions should be interpreted in the light of several important limitations. First,
caution should be used when generalizing study results and conclusions to other populations
and settings. Study cohort members were limited to insured individuals who received their
cancer care from one of four integrated health care delivery systems. Although these
samples are generally similar to the general populations in their respective communities in
terms of demographics, they may differ in other unmeasured respects. In particular, care
should be taken in generalizing our findings to those who are uninsured. Another limitation
is that we are unable to ascertain from EMR or claims-based sources whether care received
was for surveillance versus other purposes. Thus our findings of surveillance care overuse
may be partially explained by our lack of information on symptoms and laboratory findings
and our inability to differentiate between procedures received for screening versus
diagnostic purposes. However, a prior study found that claims data capturing procedures and
visit use for characterizing guideline adherence was comparable with documentation found
in the medical record, and that administrative data could be used to describe patterns of
follow up care.13 A further limitation stems from grouping patients, with heterogeneity in
prognoses, into general disease stages. Patients within these broad groups and the clinicians
treating them may resort to different surveillance practices based on perceived differences in
prognosis. Yet, it is important to note that current guidelines do not differ in their
recommendations for surveillance care based on these or other factors.
Compared to other phases of cancer control and prevention, surveillance care among cancer
survivors is understudied. Findings here highlight the wide variations that exist in cancer
surveillance care among seemingly clinically similar patients and across different age
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groups. This variation combined with the overall lack of concordance with established
clinical practice guidelines, highlights the need for research exploring both whether
observed variations are driven by patient preferences and reflect informed decision making,
and how survivorship planning as outlined by the IOM can impact such variation.
Furthermore, given the survival advantage for patients <65, it is important to consider the
care trajectory and its implications among this subset of cancer patients.
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Table 1





Mean age at diagnosis (SD) 62.4 (12.6) 68.6 (12.2)
Age at diagnosis (%)
    < 50 years 16 6
    50–64 years 41 29
    65–74 years 24 29
    ≥ 75 years 19 36
Sex (%)
    Male - 49
    Female 100 51
Race (%)
    Black 8 8
    White 81 81
    Other 11 11





    In situ 24 4
    Localized 56 45
    Regional 20 51
Site of care (%)
    Health plan 1 22 18
    Health plan 2 31 32
    Health plan 3 19 18
    Health plan 4 28 32
Treatment (%)
    Surgery 100 100
    Chemotherapy 29 33
    Hormone therapy 49 -
    Radiation therapy 61 12
    Combination treatments 70 33
Median follow-up in months 49.5 40.9
Recurred within 5 years (%) 13 22
Survived 5 years (%) 96 90
SD: Standard deviation.
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Table 3
Cox proportional hazards model: Metastatic disease testing within 18 months of treatment, among breast
cancer survivors.
Hazard Ratio (95% CI) P-value
Sociodemographic factors
   Age at diagnosis
     < 50 years 1.13 (1.01–1.27) 0.03
     50–64 years 1.15 (1.05–1.26) <0.01
     65–74 years 1.13 (1.03–1.25) 0.01
     ≥ 75 years reference -
   White 1.13 (1.03–1.23) 0.01
   Median household income ($1000s) 1.00 (1.00–1.00) 0.97
Disease stage
   In situ 0.31 (0.28–0.35) <0.01
   Localized 0.57 (0.52–0.61) <0.01
   Regional reference -
Charlson comorbidity index 1.17 (1.13–1.20) <0.01
Site of care
   Health plan 1 1.76 (1.61–1.93) <0.01
   Health plan 2 0.78 (0.71–0.85) <0.01
   Health plan 3 0.98 (0.89–1.08) 0.66
   Health plan 4 reference -
χ2 = 791.2, 11 df (p < 0.001).
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Table 4
Cox proportional hazards model: Metastatic disease testing within 18 months of treatment, among colorectal
cancer survivors.
Hazard Ratio (95% CI) P-value
Sociodemographic factors
   Age at diagnosis
      < 50 years 1.31 (1.06–1.63) 0.01
     50–64 years 1.25 (1.10–1.42) <0.01
     65–74 years 1.11 (0.98–1.26) 0.10
     ≥ 75 years reference -
   Female 1.08 (0.98–1.19) 0.13
   White 1.08 (0.95–1.24) 0.25
   Median household income ($1000s) 1.00 (1.00–1.00) 0.55
Disease stage
   In situ 0.30 (0.22–0.40) <0.01
   Localized 0.60 (0.54–0.67) <0.01
   Regional reference -
Charlson comorbidity index 1.10 (1.07–1.14) <0.01
Site of care
   Health plan 1 1.78 (1.53–2.07) <0.01
   Health plan 2 1.07 (0.94–1.21) 0.29
   Health plan 3 0.88 (0.75–1.03) 0.11
   Health plan 4 reference -
χ2 = 225.6, 12 df (p < 0.001).
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